Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH

用于 NASH 治疗应用的 LPAR1 拮抗剂的主要候选者鉴定

基本信息

  • 批准号:
    10324983
  • 负责人:
  • 金额:
    $ 39.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-20 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Summary The ultimate goal of this application is to develop one of Epigen’s proprietary antagonists of the lysophosphatidic acid receptor 1 (LPAR1) for the effective treatment of liver fibrosis associated with chronic diseases such as non- alcoholic steatohepatitis (NASH), a severe type of non-alcoholic fatty liver disease (NAFLD). NAFLD is the most common liver disease and is associated with obesity and type-2 diabetes. There are currently no effective treatments available for NASH except lifestyle changes. Preliminary data presented in this application establishes the proof-of-concept of one of Epigen’s LPAR1 lead antagonists, EPGN696, in three mouse models of NASH and liver fibrosis. In vitro mechanistic data confirms that LPAR1 antagonism blocks hepatic stellate cell proliferation, thus blocking an important fibrotic pathway. Furthermore, LPAR1 antagonists block migration of macrophages stimulated by MCP-1 indicating an anti-inflammatory mechanism. During the course of our work in kidney disease, we have identified EPGN2154, an improved LPAR1 antagonist, that has proven safe and more efficacious than EPGN696 in kidney disease models. In this phase 1 SBIR grant, we propose an approach which will involve the pre-clinical evaluation of EPGN2154 in two translational animal models of NASH. The disease will be induced for a longer period and chronic therapeutic treatment with the LPAR1 antagonists will be extended. EPGN696 will be used as a comparator in these studies. We expect that this will allow characterization of a minimum efficacious dose of EPGN2154 in NASH relevant endpoints. The successful outcome of this work will lauch efforts in toxicology and chemistry, manufacturing and controls (CMC) work to support filing of an investigational new drug (IND) application and eventually initiation of clinical trials in humans.
总结 该申请的最终目标是开发Epigen专有的溶血磷脂拮抗剂之一, 酸受体1(LPAR 1)用于有效治疗与慢性疾病如非肝性肝纤维化相关的肝纤维化。 酒精性脂肪性肝炎(NASH),一种严重类型的非酒精性脂肪性肝病(NAFLD)。NAFLD是最 常见的肝脏疾病,并与肥胖和2型糖尿病有关。目前还没有有效 治疗NASH,除了改变生活方式。本申请中提供的初步数据 在三种小鼠模型中建立了Epigen的LPAR 1先导拮抗剂EPGN 696的概念验证 NASH和肝纤维化体外机制数据证实,LPAR 1拮抗作用阻断肝星状细胞 增殖,从而阻断重要的纤维化途径。此外,LPAR 1拮抗剂阻断了 MCP-1刺激的巨噬细胞,表明抗炎机制。在我们工作的过程中, 在肾脏疾病中,我们已经确定了EPGN 2154,一种改进的LPAR 1拮抗剂,已被证明是安全的, 在肾脏疾病模型中比EPGN 696更有效。 在第一阶段SBIR资助中,我们提出了一种方法,该方法将涉及EPGN 2154的临床前评估 在NASH的两个转化动物模型中。诱发本病的时间较长,且呈慢性化 将延长使用LPAR 1拮抗剂的治疗。EPGN 696将用作对照品, 这些研究。我们预期这将允许表征在小鼠中EPGN 2154的最小有效剂量。 NASH相关终点。这项工作的成功结果将在毒理学和化学方面做出努力, 生产和控制(CMC)工作,以支持研究性新药(IND)申请的提交, 最终开始人体临床试验。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models.
  • DOI:
    10.1097/hc9.0000000000000323
  • 发表时间:
    2023-12-01
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fabio Cohen Tucci其他文献

Fabio Cohen Tucci的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Fabio Cohen Tucci', 18)}}的其他基金

Assessment of a selective kinase inhibitor in pre-clinical models of NASH
NASH 临床前模型中选择性激酶抑制剂的评估
  • 批准号:
    10080619
  • 财政年份:
    2020
  • 资助金额:
    $ 39.74万
  • 项目类别:
The role of selective brain penetrating GRPR antagonists in pruritis.
选择性脑穿透 GRPR 拮抗剂在瘙痒症中的作用。
  • 批准号:
    8338820
  • 财政年份:
    2011
  • 资助金额:
    $ 39.74万
  • 项目类别:
The role of selective brain penetrating GRPR antagonists in pruritis.
选择性脑穿透 GRPR 拮抗剂在瘙痒症中的作用。
  • 批准号:
    8236621
  • 财政年份:
    2011
  • 资助金额:
    $ 39.74万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 39.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了